Naya Biosciences, INC

INVO Fertility Inc. has entered into an "Any Market Purchase Agreement" with Alumni Capital LP, establishing a flexible equity financing facility of up to $15 million, potentially extendable to $50 million.

INVO Fertility has acquired full ownership of its Alabama joint venture clinic and resolved Nasdaq listing compliance issues.

INVO Fertility, Inc. has released an updated investor presentation ahead of its participation in the Planet MicroCap Conference.

INVO Fertility, Inc. announced its fiscal year 2025 financial results, reporting a 5% increase in revenue to $6.84 million and a narrowed net loss from continuing operations, while also highlighting recent financing and strategic expansions.

INVO Fertility, Inc. announced that previously issued financial statements for periods ending March 31, June 30, and September 30, 2025, must be restated due to accounting errors related to derivative and debt extinguishment.

INVO Fertility, Inc. has successfully closed the acquisition of Family Beginnings, P.C., expanding its network of fertility care centers and broadening patient access to advanced reproductive care.

INVO Fertility, Inc. reported a significant net loss for the nine months ended September 30, 2025, driven by the divestiture of NAYA Therapeutics and related impairment charges, despite revenue growth in its core fertility clinic services.

INVO Fertility, Inc. divests majority stake in NAYA Therapeutics to refocus on core fertility business, reporting significant net losses and ongoing liquidity challenges in its latest quarterly filing.

INVO Fertility reports its Q1 2025 financial results while strategically refocusing on its fertility business and planning the divestiture of its majority stake in NAYA Therapeutics.

NAYA Biosciences' third quarter 2024 results show significant revenue growth primarily driven by the acquisition of the Wisconsin Fertility Institute.

NAYA Biosciences has amended its Q2 2024 report to restate previous financial statements due to an error in lease accounting, while also reporting a net loss for the quarter.

INVO Bioscience saw a significant revenue increase in the second quarter of 2024, primarily due to the acquisition of the Wisconsin Fertility Institute.

INVO Fertility, Inc. filed an amendment to its 2025 Annual Report to provide required Part III proxy information and updated certifications.

INVO Fertility, Inc. outlines its authorized capital stock, including common and various series of preferred stock, detailing their rights and conversion terms.

INVO Fertility files an amendment to its 2024 annual report on Form 10-K to include its Clawback Policy and related disclosures regarding executive compensation recovery.

INVO Fertility, formerly NAYA Biosciences, will refocus on its fertility business and divest its NAYA Therapeutics subsidiary after failing to gain shareholder support for key transaction elements.

NAYA Biosciences restated its financial statements for multiple periods due to an error in calculating lease discount rates, while also reporting its full year 2023 results including a significant increase in clinic revenue and a net loss.

INVO Bioscience has filed an amendment to its annual report on Form 10-K, primarily to include information required by Part III of the form and updated certifications, while also detailing executive compensation, board composition, and the proposed merger with NAYA Biosciences.

INVO Fertility Director Matthew K Szot reported selling 4 shares and surrendering 3 shares of common stock, while holding adjusted stock options.

INVO Fertility, Inc. CEO Steve Shum was granted 42,000 stock options with an exercise price of $1.01, vesting over four quarters starting October 2025.

INVO Fertility, Inc. Director Matthew K Szot reported the acquisition of 45,000 stock options and beneficial ownership of common stock.

INVO Fertility, Inc. Director Barbara Ryan was granted 45,000 stock options and acquired 46 shares of common stock.

INVO Fertility's Chief Financial Officer, Andrea Goren, was granted 50,000 stock options with a $1.01 exercise price, vesting over four quarters.

INVO Fertility, Inc. Director Trent D. Davis acquired 45,000 stock options and disposed of 49 common shares, as reported in a recent SEC Form 4 filing.

INVO FERTILITY, INC. has filed a Definitive Proxy Statement with the SEC, soliciting shareholder votes for upcoming matters.

INVO Fertility, Inc. calls a special meeting to ratify a new auditor, approve significant share issuances for a private placement, and dramatically increase authorized common stock, amidst ongoing financial concerns.

INVO Fertility, Inc. filed a supplement to its 2025 Annual Meeting proxy statement, confirming updated meeting details, announcing a 1-for-3 reverse stock split effective July 21, 2025, and correcting the voting standard for a proposal to increase authorized common stock.

INVO FERTILITY, INC. has filed a definitive proxy statement with the U.S. Securities and Exchange Commission under Schedule 14A.

INVO Fertility, Inc. is calling its 2025 Annual Meeting of Stockholders to vote on critical proposals including a significant increase in authorized common stock, conversion of preferred shares and debentures, and amendments to its stock incentive plan, following a strategic divestment of its NAYA TX biopharma holdings and a prior financial restatement.

NAYA Biosciences has postponed its 2024 Annual Meeting of Stockholders to April 9, 2025, and filed an amended proxy statement due to insufficient votes on special proposals.

INVO Fertility, Inc. has filed an S-1 registration statement to allow for the resale of up to 20,000,000 shares of common stock by Alumni Capital LP.

INVO Fertility, Inc. files an S-1 registration statement for the resale of up to 9.4 million common shares by Armistice Capital, stemming from a recent warrant inducement agreement.

INVO Fertility, Inc. filed an S-1 registration statement for the resale of up to 7.37 million common shares by existing stockholders and announced the acquisition of fertility practice Family Beginnings for $750,000.

INVO Fertility, Inc. filed an S-1 registration statement for the resale of up to 8,345,774 shares of common stock by Five Narrow Lane LP, with no direct proceeds to the company from the sale.

NAYA Biosciences enters into a warrant agency agreement with Transfer Online, Inc. for its public offering involving common stock, pre-funded warrants, and common stock purchase warrants.

NAYA Biosciences has filed an amendment to its registration statement for a unit offering of up to $13 million, including common stock or pre-funded warrants and common warrants.

Armistice Capital, LLC and Steven Boyd have jointly filed a Schedule 13G, reporting beneficial ownership of 9.99% of INVO Fertility, Inc. common stock as of March 31, 2026.

Glenbrook Capital Management has reported a beneficial ownership of 8.33% of INVO Fertility, Inc.'s common stock, totaling 134,515 shares.

Five Narrow Lane LP filed an amended Schedule 13G, reporting beneficial ownership of 0.29% of INVO Fertility, Inc.'s common stock.

Greenblock Capital, LLC and its manager Christopher Spencer have disclosed a 9.99% beneficial ownership stake in INVO Fertility, Inc., totaling 617,954 common shares.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has filed an amended Schedule 13G disclosing a beneficial ownership of 4.99% in INVO Fertility, Inc.'s common stock.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, has disclosed a beneficial ownership of 6.9% in NAYA Biosciences Inc. common stock, totaling 504,478 shares.